Acurx Pharmaceuticals, INC 8-K filings

Acurx Pharmaceuticals has entered into a definitive agreement for a registered direct offering and concurrent private placement to raise approximately $2.5 million in gross proceeds.

Acurx Pharmaceuticals, Inc. stockholders approved an amendment to increase authorized common stock from 200 million to 250 million shares.

Acurx Pharmaceuticals' stockholders approved the issuance of shares underlying Series G-2 warrants and an increase in authorized common stock from 200 million to 250 million shares.

Acurx Pharmaceuticals, a late-stage biopharmaceutical company, announced a 1-for-20 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Acurx Pharmaceuticals, Inc. shareholders approved all six proposals at its Annual Meeting, including a reverse stock split, the issuance of shares for warrant exercises and an equity line of credit, and an increase in the 2021 Equity Incentive Plan.

Acurx Pharmaceuticals, Inc. has entered into a warrant inducement agreement, generating approximately $2.3 million in net proceeds by inducing the exercise of existing warrants at a reduced price and issuing new, highly dilutive warrants.

Acurx Pharmaceuticals announced its Q1 2025 financial results and provided a business update, highlighting progress with ibezapolstat and new patents.

Acurx Pharmaceuticals has entered into a purchase agreement with Lincoln Park Capital for up to $12 million in shares of common stock to fund working capital and general corporate purposes.

Acurx Pharmaceuticals received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Acurx Pharmaceuticals reported its Q4 and full year 2024 financial results, emphasizing positive clinical data and regulatory advancements for its lead antibiotic candidate, ibezapolstat.

Acurx Pharmaceuticals, Inc. has entered into a definitive agreement for a registered direct offering of common stock and warrants, expected to close around March 10, 2025, to raise approximately $1.1 million.

Acurx Pharmaceuticals received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them until August 25, 2025, to regain compliance.

Acurx Pharmaceuticals has entered into a definitive agreement for a $2.5 million registered direct offering of common stock and warrants.

Acurx Pharmaceuticals reported its third quarter 2024 financial results, highlighted by progress in clinical trials and patent approvals for its lead antibiotic candidate, ibezapolstat.

Acurx Pharmaceuticals reported its second quarter 2024 financial results, highlighted by progress in its ibezapolstat clinical program and regulatory advancements.

Acurx Pharmaceuticals held its annual meeting on June 17, 2024, where shareholders elected three Class III directors and ratified the appointment of CohnReznick LLP as the company's independent auditor for the fiscal year ending December 31, 2024.

Acurx Pharmaceuticals announced positive Phase 2 clinical trial data for ibezapolstat and its first quarter 2024 financial results, including an increase in cash and operating expenses.

Acurx Pharmaceuticals reported positive results from its Phase 2b clinical trial for ibezapolstat, showing high cure rates for C. difficile infection, and provided a financial update including a cash balance of $7.5 million at the end of 2023.